COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,304 Articles (22,772 medRxiv, 8,532 bioRxiv)

Most recent first Previous |  Page 1412: Articles 14111-14120  | Next

Predictors of Depression and Anxiety Symptoms in Brazil during COVID-19
Zhang, S. X., Huang, H., Li, J., Mayra, A.-P., Scheila, d. P. F., Jose, d. S. A.
10.1101/2021.06.28.21259409 — Posted: 2021-07-03
A new model of unreported COVID-19 cases outperforms three known epidemic-growth models in describing data from Cuba and Spain
Ramirez-Torres, E. E., Castaneda, A. R. S., Randez, L., Garcia, L. E. V., Cabrales, L. E. B., Sisson, S. A., Montijano, J. I.
10.1101/2021.06.29.21259707 — Posted: 2021-07-03
The Impact of Non-Pharmaceutical Interventions on the First COVID-19 Epidemic Wave in South Africa
Mabuka, T., Ncube, N., Ross, M., Silaji, A., Macharia, W., Ndemera, T., Lemeke, T.
10.1101/2021.06.29.21259625 — Posted: 2021-07-03
Prominent Spatiotemporal Waves of COVID-19 Incidence in the United States: Implications for Causality, Forecasting, and Control
Jalal, H., Lee, K., Burke, D. S.
10.1101/2021.06.29.21259726 — Posted: 2021-07-03
Modeling robust COVID-19 intensive care unit occupancy thresholds for imposing mitigation to prevent exceeding capacities
Runge, M., Richardson, R. A. K., Clay, P., Eagan, A., Holden, T. M., Singam, M., Tsuboyama, N., Arevalo, P., Fornoff, J., Patrick, S., Ezike, N. O., Gerardin, J.
10.1101/2021.06.27.21259530 — Posted: 2021-07-03
SARS-CoV-2 vaccine breakthrough infections are asymptomatic or mildly symptomatic and are infrequently transmitted.
Rovida, F., Cassaniti, I., Paolucci, S., Percivalle, E., Sarasini, A., Piralla, A., Giardina, F., Sammartino, J. C., Ferrari, A., Bergami, F., Muzzi, A., Novelli, V., Meloni, A., Grugnetti, A. M., Grugnetti, G., Rona, C., Daglio, M., Marena, C., Triarico, A., Lilleri, D., Baldanti, F.
10.1101/2021.06.29.21259500 — Posted: 2021-07-03 Discussion: Onsite | Offsite
Longitudinal testing for SARS-CoV-2 RNA in day care centers in Hesse, Germany, during increased local incidence and with VOC Alpha as dominant variant: Results of the SAFE KiDS 2 and SAFE KiDS 3 study
Schenk, B., Hoehl, S., Rudych, O., Kreutzer, E., Menger, D., Farmand, S., Gebert, D., Flohr, M., Berger, F., Wrobel, F., Weigel, V., Kortenbusch, M., Berger, A., Ciesek, S.
10.1101/2021.06.29.21259633 — Posted: 2021-07-03
Convalescent plasma for hospitalized patients with COVID-19 and the effect of plasma antibodies: a randomized controlled, open-label trial
Begin, P., Callum, J., Jamula, E. J., Cook, R., Heddle, N. M., Tinmouth, A., Zeller, M. P., Beaudoin-Bussiere, G., Amorim, L., Bazin, R., Cadogan Lofstgard, K., Carl, R., Chasse, M., Cushing, M., Daneman, N., Devine, D. V., Dumaresq, J., Ferguson, D., Gabe, C., Glesby, M. J., Li, N., Liu, Y., McGeer, A., Robitaille, N., Sachais, B. S., Scales, D. C., Schwartz, L., Shehata, N., Turgeon, A., Wood, H., Zarychanski, R., Finzi, A., Arnold, D. M., CONCOR-1 Study Group
10.1101/2021.06.29.21259427 — Posted: 2021-07-03
Prospective sero surveillance among healthcare workers vaccinated with ChAdOx1 nCoV-19 Corona vaccine in a tertiary hospital of Kerala, India
Njarekkattuvalappil, S. K., Bhaskaran, R., Vijaya Raj, S. R., Jose, P., Rafi, A. M., Thomas, J., Innah, S., Raphael, L., G, U. U., R, P., Valsan, C., Kuttichira, P.
10.1101/2021.06.29.21259686 — Posted: 2021-07-03
SARS-CoV-2 Lambda Variant Remains Susceptible to Neutralization by mRNA Vaccine-elicited Antibodies and Convalescent Serum
Tada, T., Zhou, H., Dcosta, B. M., Samanovic, M. I., Mulligan, M. J., Landau, N. R.
10.1101/2021.07.02.450959 — Posted: 2021-07-03

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).